Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 2/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 10/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26836187 | 0.78 | ESR1 (0.47) | TBXAS1NAMPTESR1HDAC1MGLL | |
| SCHEMBL26414011 | 0.78 | TBXAS1 (0.47) | TBXAS1NAMPTESR1HDAC1 | |
| SCHEMBL322086 | 0.74 | NAMPT (0.46) | TBXAS1NAMPTESR1HDAC1 | |
| SCHEMBL30147831 | 0.74 | NAMPT (0.52) | TBXAS1NAMPTESR1HDAC1 | |
| SCHEMBL26103112 | 0.72 | HPGD (0.51) | TBXAS1NAMPTDDR1 | |
| SCHEMBL15825109 | 0.70 | TBXAS1 (0.53) | TBXAS1NAMPTESR1HDAC1 | |
| SCHEMBL21580165 | 0.70 | NAMPT (0.69) | TBXAS1NAMPTHDAC1 | |
| SCHEMBL29683753 | 0.70 | HDAC1 (0.48) | TBXAS1NAMPTESR1HDAC1DDR1 | |
| SCHEMBL31285117 | 0.70 | DDR1 (0.49) | TBXAS1NAMPTESR1HDAC1MGLL | |
| SCHEMBL20305483 | 0.70 | ESR1 (0.44) | TBXAS1NAMPTESR1HDAC1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389005-A1 | 7,8-DIHYDROBENZO[E]PYRIDO[3,4-C]AZOCINE-2,5(3H,6H)-DIONE DERIVATIVES USEFUL AS A FACTOR XIA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389005-A1 | 7,8-DIHYDROBENZO[E]PYRIDO[3,4-C]AZOCINE-2,5(3H,6H)-DIONE DERIVATIVES USEFUL AS A FACTOR XIA INHIBITORS | F2, F13B, SERPINE1 | TBXAS1 64/4885NAMPT 3829/4885ESR1 2512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.